Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hutchison MediPharma Raises $12.5 Million from Mitsui

publication date: Nov 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, a subsidiary of Chi-Med, announced a $12.5 million investment from Mitsui & Co., which received convertible Preference Shares that convert into 12.2% of Hutchison MediPharma. The transaction implies a $100 million valuation for the company, which is the drug discovery arm of Chi-Med. MediPharma said the money would support its various drug development programs. More details....

Stock Symbol: (AIM: HCM)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...